1. Home
  2. FOSL vs LXEO Comparison

FOSL vs LXEO Comparison

Compare FOSL & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fossil Group Inc.

FOSL

Fossil Group Inc.

HOLD

Current Price

$5.87

Market Cap

339.5M

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.07

Market Cap

348.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOSL
LXEO
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
339.5M
348.7M
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
FOSL
LXEO
Price
$5.87
$4.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$7.00
$18.44
AVG Volume (30 Days)
650.1K
645.2K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
25.26
39.81
EPS
N/A
N/A
Revenue
$1,004,406,000.00
$654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$3.99
52 Week High
$6.25
$10.99

Technical Indicators

Market Signals
Indicator
FOSL
LXEO
Relative Strength Index (RSI) 62.83 33.74
Support Level $3.83 $4.01
Resistance Level $6.05 $5.38
Average True Range (ATR) 0.30 0.23
MACD 0.07 -0.06
Stochastic Oscillator 97.39 5.10

Price Performance

Historical Comparison
FOSL
LXEO

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: